CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis

Caterina Ieranò, Luigi Portella, Sara Lusa, Giuseppina Salzano, Crescenzo D'Alterio, Maria Napolitano, Maria Buoncervello, Daniele Macchia, Massimo Spada, Antonio Barbieri, Antonio Luciano, Maria Vittoria Barone, Lucia Gabriele, Michele Caraglia, Claudio Arra, Giuseppe De Rosa, Stefania Scala

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The chemokine CXCL12 activates CXCR4, initiating multiple pathways that control immune cell trafficking, angiogenesis and embryogenesis; CXCR4 is also overexpressed in multiple tumors affecting metastatic dissemination. While there has been great enthusiasm for exploiting the CXCR4-CXCL12 axis as a target in cancer therapy, to date the promise has yet to be fulfilled. A new class of CXCR4-antagonist cyclic peptides was recently developed and the compound named Peptide R was identified as the most active. With the intent to improve the efficacy and biodistribution of Peptide R, stealth liposomes decorated with Peptide R were developed (PL-Peptide R). In vitro PL-Peptide R efficiently inhibited CXCR4-dependent migration and in vivo it significantly reduced lung metastases and increased overall survival in B16-CXCR4 injected C57BL/6 mice. To evaluate if PL-Peptide R could also be a drug delivery system for CXCR4 expressing tumors, the PL-Peptide R was loaded with doxorubicin (DOX) (PL-Peptide R-DOX). PL-Peptide R-DOX efficiently delivered DOX to CXCR4 expressing cell lines with a consequent decrease in the DOX IC50 efficient dose. In vivo, B16-CXCR4 injected C57BL/6 mice treated with PL-Peptide R-DOX developed fewer lung metastases compared to PL-DOX treated mice. This work provides the proof-of-concept to prevent metastasis by using combined nanomedicine.

Original languageEnglish
Pages (from-to)7562-7571
Number of pages10
JournalNanoscale
Volume8
Issue number14
DOIs
Publication statusPublished - Apr 14 2016

Fingerprint

Liposomes
Peptides
Doxorubicin
Tumors
R peptide
Medical nanotechnology
Chemokine CXCL12
Cyclic Peptides
Cells

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. / Ieranò, Caterina; Portella, Luigi; Lusa, Sara; Salzano, Giuseppina; D'Alterio, Crescenzo; Napolitano, Maria; Buoncervello, Maria; Macchia, Daniele; Spada, Massimo; Barbieri, Antonio; Luciano, Antonio; Barone, Maria Vittoria; Gabriele, Lucia; Caraglia, Michele; Arra, Claudio; De Rosa, Giuseppe; Scala, Stefania.

In: Nanoscale, Vol. 8, No. 14, 14.04.2016, p. 7562-7571.

Research output: Contribution to journalArticle

Ieranò, C, Portella, L, Lusa, S, Salzano, G, D'Alterio, C, Napolitano, M, Buoncervello, M, Macchia, D, Spada, M, Barbieri, A, Luciano, A, Barone, MV, Gabriele, L, Caraglia, M, Arra, C, De Rosa, G & Scala, S 2016, 'CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis', Nanoscale, vol. 8, no. 14, pp. 7562-7571. https://doi.org/10.1039/c5nr06335c
Ieranò C, Portella L, Lusa S, Salzano G, D'Alterio C, Napolitano M et al. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Nanoscale. 2016 Apr 14;8(14):7562-7571. https://doi.org/10.1039/c5nr06335c
Ieranò, Caterina ; Portella, Luigi ; Lusa, Sara ; Salzano, Giuseppina ; D'Alterio, Crescenzo ; Napolitano, Maria ; Buoncervello, Maria ; Macchia, Daniele ; Spada, Massimo ; Barbieri, Antonio ; Luciano, Antonio ; Barone, Maria Vittoria ; Gabriele, Lucia ; Caraglia, Michele ; Arra, Claudio ; De Rosa, Giuseppe ; Scala, Stefania. / CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. In: Nanoscale. 2016 ; Vol. 8, No. 14. pp. 7562-7571.
@article{b0b3f0933739435d8f960e16a98987b7,
title = "CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis",
abstract = "The chemokine CXCL12 activates CXCR4, initiating multiple pathways that control immune cell trafficking, angiogenesis and embryogenesis; CXCR4 is also overexpressed in multiple tumors affecting metastatic dissemination. While there has been great enthusiasm for exploiting the CXCR4-CXCL12 axis as a target in cancer therapy, to date the promise has yet to be fulfilled. A new class of CXCR4-antagonist cyclic peptides was recently developed and the compound named Peptide R was identified as the most active. With the intent to improve the efficacy and biodistribution of Peptide R, stealth liposomes decorated with Peptide R were developed (PL-Peptide R). In vitro PL-Peptide R efficiently inhibited CXCR4-dependent migration and in vivo it significantly reduced lung metastases and increased overall survival in B16-CXCR4 injected C57BL/6 mice. To evaluate if PL-Peptide R could also be a drug delivery system for CXCR4 expressing tumors, the PL-Peptide R was loaded with doxorubicin (DOX) (PL-Peptide R-DOX). PL-Peptide R-DOX efficiently delivered DOX to CXCR4 expressing cell lines with a consequent decrease in the DOX IC50 efficient dose. In vivo, B16-CXCR4 injected C57BL/6 mice treated with PL-Peptide R-DOX developed fewer lung metastases compared to PL-DOX treated mice. This work provides the proof-of-concept to prevent metastasis by using combined nanomedicine.",
author = "Caterina Ieran{\`o} and Luigi Portella and Sara Lusa and Giuseppina Salzano and Crescenzo D'Alterio and Maria Napolitano and Maria Buoncervello and Daniele Macchia and Massimo Spada and Antonio Barbieri and Antonio Luciano and Barone, {Maria Vittoria} and Lucia Gabriele and Michele Caraglia and Claudio Arra and {De Rosa}, Giuseppe and Stefania Scala",
year = "2016",
month = "4",
day = "14",
doi = "10.1039/c5nr06335c",
language = "English",
volume = "8",
pages = "7562--7571",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "14",

}

TY - JOUR

T1 - CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis

AU - Ieranò, Caterina

AU - Portella, Luigi

AU - Lusa, Sara

AU - Salzano, Giuseppina

AU - D'Alterio, Crescenzo

AU - Napolitano, Maria

AU - Buoncervello, Maria

AU - Macchia, Daniele

AU - Spada, Massimo

AU - Barbieri, Antonio

AU - Luciano, Antonio

AU - Barone, Maria Vittoria

AU - Gabriele, Lucia

AU - Caraglia, Michele

AU - Arra, Claudio

AU - De Rosa, Giuseppe

AU - Scala, Stefania

PY - 2016/4/14

Y1 - 2016/4/14

N2 - The chemokine CXCL12 activates CXCR4, initiating multiple pathways that control immune cell trafficking, angiogenesis and embryogenesis; CXCR4 is also overexpressed in multiple tumors affecting metastatic dissemination. While there has been great enthusiasm for exploiting the CXCR4-CXCL12 axis as a target in cancer therapy, to date the promise has yet to be fulfilled. A new class of CXCR4-antagonist cyclic peptides was recently developed and the compound named Peptide R was identified as the most active. With the intent to improve the efficacy and biodistribution of Peptide R, stealth liposomes decorated with Peptide R were developed (PL-Peptide R). In vitro PL-Peptide R efficiently inhibited CXCR4-dependent migration and in vivo it significantly reduced lung metastases and increased overall survival in B16-CXCR4 injected C57BL/6 mice. To evaluate if PL-Peptide R could also be a drug delivery system for CXCR4 expressing tumors, the PL-Peptide R was loaded with doxorubicin (DOX) (PL-Peptide R-DOX). PL-Peptide R-DOX efficiently delivered DOX to CXCR4 expressing cell lines with a consequent decrease in the DOX IC50 efficient dose. In vivo, B16-CXCR4 injected C57BL/6 mice treated with PL-Peptide R-DOX developed fewer lung metastases compared to PL-DOX treated mice. This work provides the proof-of-concept to prevent metastasis by using combined nanomedicine.

AB - The chemokine CXCL12 activates CXCR4, initiating multiple pathways that control immune cell trafficking, angiogenesis and embryogenesis; CXCR4 is also overexpressed in multiple tumors affecting metastatic dissemination. While there has been great enthusiasm for exploiting the CXCR4-CXCL12 axis as a target in cancer therapy, to date the promise has yet to be fulfilled. A new class of CXCR4-antagonist cyclic peptides was recently developed and the compound named Peptide R was identified as the most active. With the intent to improve the efficacy and biodistribution of Peptide R, stealth liposomes decorated with Peptide R were developed (PL-Peptide R). In vitro PL-Peptide R efficiently inhibited CXCR4-dependent migration and in vivo it significantly reduced lung metastases and increased overall survival in B16-CXCR4 injected C57BL/6 mice. To evaluate if PL-Peptide R could also be a drug delivery system for CXCR4 expressing tumors, the PL-Peptide R was loaded with doxorubicin (DOX) (PL-Peptide R-DOX). PL-Peptide R-DOX efficiently delivered DOX to CXCR4 expressing cell lines with a consequent decrease in the DOX IC50 efficient dose. In vivo, B16-CXCR4 injected C57BL/6 mice treated with PL-Peptide R-DOX developed fewer lung metastases compared to PL-DOX treated mice. This work provides the proof-of-concept to prevent metastasis by using combined nanomedicine.

UR - http://www.scopus.com/inward/record.url?scp=84963628598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963628598&partnerID=8YFLogxK

U2 - 10.1039/c5nr06335c

DO - 10.1039/c5nr06335c

M3 - Article

AN - SCOPUS:84963628598

VL - 8

SP - 7562

EP - 7571

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 14

ER -